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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease.
There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of
cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and
their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls.
Methods: We evaluated 2445 CKD patients (2010–2012). The information collected was: clinical, anthropometric
and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque
presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years.
Results: ADPKD patients had a worse renal function and worst achievement of blood pressure, higher
parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than
other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than
half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe
respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK
had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221–0.808, p = 0.009).
Conclusion: ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be
related with a lower load of CVD compared to other groups, which may lead in the long term to a better
prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD.
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Introduction
Cardiovascular disease (CVD) is the leading cause of
death in patients with chronic kidney disease (CKD)
from earlier stages of the disease compared to the
general population [1, 2]. Consequently, CKD has been
considered an important cardiovascular risk factor in
several international guidelines. In this regard, several
factors have been postulated to contribute to this
increased risk, mainly, age at CKD initiation and comor-
bidities such as arterial hypertension and diabetes,
followed by other related conditions such as obesity or
dyslipidemia [3]. On the other hand, CKD per se
produces several alterations that have a direct impact on
vascular health, such as proteinuria, anemia, metabolic
acidosis or mineral bone disease (MBD). These lastly is
known as non-traditional or uremic related factors.
Some of these factors may partially explain the higher
rates of both asymptomatic CVD and cardiovascular
events (CVE) among CKD patients.
Autosomal dominant polycystic kidney disease (ADPK
D) is the most frequent hereditary renal disease and
accounts for approximately 6 to 10% of the patients
initiating renal replacement therapies (RRT) worldwide
[2, 4]. Although ADPKD is not usually associated with
diabetic or hypertensive nephropathy, there is an in-
creased in the rate of CVD in ADPKD patients being the
first cause of death (Fig. 1) [5, 6]. It should be noted that
there is evidence that asymptomatic CVD predicts the
incidence of CVE [7], but data on evaluation and man-
agement of cardiovascular risk in ADPKD are limited.
This study evaluates the prevalence of classic cardio-
vascular risk factors in ADPKD, its relationships to
asymptomatic CVD and treatment trends in ADPKD
patients in a large cohort of CKD patients and controls
without previous CVD.
Material and methods
Study design and participants
This study is a sub-analysis of the NEFRONA project,
which consists of a large prospective multicenter cohort
designed to evaluate asymptomatic CVD in patients at
different stages of CKD without previous CVE. Extensive
information on methodology and initial results has been
published previously [8, 9]. In summary, from October
2010 to June 2012, 2445 patients with CKD (937 CKD
stage 3, 820 CKD stages 4–5 and 688 in dialysis) were
enrolled in 81 hospitals and dialysis units throughout
Spain, along with 559 patients without CKD used as
Fig. 1 Pathophysiological mechanisms associated with the initiation and progression of chronic kidney disease in autosomal dominant polycystic
kidney disease. This schematic figure shows the negative influence of classical and renal or uremic-related cardiovascular risk factors in patients
affected by ADPKD. The key to management these patients depend of the optimal approach and good control of these associated risk factors.
The uses of novel therapies as vasopressin V2-receptor antagonist (Tolvaptan) may delay the progression of the renal disease specifically at the
first step of the pathophysiological mechanisms related to proliferation and expansion of the cyst. Finally, if these measures are not taking in the
early stages of ADPKD, a cascade of events can develop serious consequences. In addition, an activation of SRAA and SNS may produce vascular
damage, increase the vascular resistance and renal fibrosis. All these activated mechanisms induce a chronic and irreversible damage in the
kidneys. Abbreviations: SRAA, renin – angiotensin – aldosterone system; SNS, sympathetic nervous system; ADPKD, autosomal dominant
polycystic kidney disease; CVD, cardiovascular disease; CKD, chronic kidney disease
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controls, also without previous CVE selected from 14
Spanish primary care centers. Controls did not have
CKD but were not completely healthy subjects, as they
attended primary care due to different comorbidities.
A biannual follow-up was conducted over 4 years. The
patients signed the informed consent and the study
protocol was approved by the Ethics Committee of the
Arnau de Vilanova University Hospital.
For this sub-study, 1192 patients with diabetes or on
dialysis were excluded to avoid the confusing effect of
these circumstances. Finally, a total of 1.751 patients
were included: 132 patients with ADPKD were com-
pared with 1121 patients with CKD of other etiologies
(CKDoe) and 498 controls (Fig. 2).
Clinical data
The information collected at the baseline and at 24
months was as follow: clinical and anthropometric data,
analytical parameters (including renal function, meta-
bolic profiles, anemia, CKD-related MBD and inflamma-
tion parameters), pharmacological treatments and the
evaluation CVD using the intima-media thickness
(IMT), the presence of carotid atheromatous plaque and
the ankle-brachial index (ABI). All anthropometric and
cardiovascular evaluations were performed using a stan-
dardized method by three experienced itinerant teams.
The occurrence of fatal and non-fatal CVE was evaluated
biannually, as well as the death from other causes and
kidney transplantation. Laboratory data, vital status,
cardiovascular events and hospitalizations were collected
every 2 years and at the end of the study (48 months).
Patients with ADPKD were compared to non-CKD
patients and patients with CKDoe. In order to assess the
specific impact of ADPKD and exclude the added effect
of advanced CKD, a secondary analysis was performed
comparing only patients with CKD stage 3 an ADPKD
with controls.
The adequacy of cardiovascular risk factors control
across groups was compared (hypertension, dyslipidemia,
obesity, and treatment with statins and renin-angiotensin-
aldosterone system [RAAS] blockade). Adequate blood
pressure control was considered when the office blood
pressure was < 140/90mmHg [10]. Proper cholesterol
control was considered when LDL-cholesterol was < 155
mg/dL in non-CKD patients or < 100mg/dL in CKD
patients [11].
Statistical analysis
Statistical analyses were performed with SPSS version
20.0 software (Chicago, Ill, USA). Mean value ± standard
deviation is used for quantitative data, while absolute
and relative frequencies are used for qualitative variables.
The Kolmogorov-Smirnoff test was used to confirm the
normal distribution. The Χ2 test was used to compare
categorical data, Student’s t-test for continuous data
between two groups and ANOVA for multinomial com-
parisons. Cox regression analysis was used for temporal
events. A significance level of 0.05 was accepted.
Fig. 2 Flowchart describing the patient selection. Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney
disease; CKDoe, CKD of etiologies other than ADPKD
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Results
ADPKD patients compared to CKDoe patients
The differences between patients with ADPKD and
those with CKDoe and controls are summarized in
Table 1 and supplemental Table 1 (S1). In the ADPKD
group, the distribution by age and gender was similar to
the controls, while patients with CKDoe, who were older
and with a higher prevalence of males. In terms of
comorbidities, patients with CKDoe showed more
peripheral vascular disease, presence of carotid atheroma-
tous plaque and obesity. Several differences in serum blood
and urinary parameters were detected. The patients with
ADPKD included in the study had worse renal function
(worse mean estimated by glomerular filtration rate [eGFR],
more in patients with CKD stage 4) and consequence lower
hemoglobin levels, higher parathormone levels but lower
proteinuria compared to CKDoe. It should be note that in
the evaluation of asymptomatic CVD, patients with ADPK
Table 1 Comparison between controls, ADPKD patients and patients with CKD from other etiologies. The first “p” value corresponds
to the comparison between the three groups and the second value corresponds to the comparison between ADPKD and patients
with CKD from other etiologies (CKD stages 3, 4 and 5 not on dialysis)
Controls
n = 498 (28.4%)
ADPKD
n = 132 (7.5%)
CKDoe






Age (years) 53.69 ± 1163 53.60 ± 11.09 59.56 ± 12.22 < 0.001 < 0.001
Male gender 262 (52.5%) 67 (50.8%) 700 (62.1%) < 0.001 0.012
BMI (Kg/m2) 27.82 ± 4.40 27.55 ± 4.65 28.56 ± 4.94 0.003 0.02
Obesity (BMI > 30 Kg/m2) 131 (26.3%) 35 (26.5%) 251 (34.9%) 0.010 0.03
Active smoking 100 (20.0%) 34 (25.7%) 212 (18.7%) NS NS
Hypertension 163 (32.7%) 123 (93.2%) 1017 (90.2%) < 0.001 NS
Dyslipidemia 157 (31.5%) 82 (62.1%) 762 (67.6%) < 0.001 NS
CKD stage 3 0 (0.0%) 57 (43.2%) 635 (56.3%) < 0.001 0.004
CKD stages 4–5 0 (0.0%) 75 (56.8%) 493 (43.7%) < 0.001 0.004
Creatinine (mg/dL) 0.84 ± 0.15 3.00 ± 1.77 2.37 ± 1.18 < 0.001 < 0.001
eGFR (mL/min/1.73m2) 91.82 ± 16.94 27.50 ± 14.09 33.46 ± 14.05 < 0.001 < 0.001
Hemoglobin (g/dL) 14.54 ± 1.41 12.82 ± 1.49 13.3 ± 1.73 < 0.001 0.024
Albumin (g/dL) 4.36 ± 0.30 4.08 ± 0.43 4.09 ± 0.45 < 0.001 NS
Uric acid (mg/dL) 5.05 ± 1.45 7.00 ± 1.30 6.86 ± 1.57 < 0.001 NS
Phosphate (mg/dL) 3.46 ± 0.52 4.02 ± 0.77 3.64 ± 0.76 < 0.001 NS
iPTH (pg/mL) 53.54 ± 15.34 172.26 ± 141.96 128.37 ± 110.75 < 0.001 < 0.001
25-hydroxi-vitamin D (ng/mL) 20.58 ± 8.39 18.13 ± 8.21 16.75 ± 7.47 < 0.001 NS
FGF23 (pg/mL) 53.97 ± 62.88 96.77 ± 78.44 97.71 ± 84.06 < 0.001 NS
Potassium (mEq/L) 4.47 ± 0.40 4.71 ± 0.51 4.75 ± 0.53 < 0.001 NS
Proteinuria (g/day) 0.07 ± 0.12 0.32 ± 0.38 0,98 ± 1.4 < 0.001 0.04
Urine albumin to creatinine
ratio (mg/g)
34 ± 46 214 ± 507 427 ± 894 < 0.001 0.002
SBP (mmHg) 132.45 ± 17.44 140.83 ± 19.56 142.99 ± 20.73 < 0.001 NS
DBP (mmHg) 79.84 ± 9.66 85.14 ± 10.34 82.49 ± 10.86 < 0.001 0.006
IMT (mm) 0.70 ± 0.12 0.66 ± 0.11 0.72 ± 0.14 < 0.001 < 0.001
Pathologic ABI (< 0.9 or > 1.4) 62 (12.4%) 19 (14.4%) 244 (21.8) < 0.001 0.027
Ischemic ABI (< 0.9) 56 (11.4%) 14 (11.0%) 184 (17.4%) 0.004 0.041
Plaque presence 248 (49.7%) 71 (53.8%) 752 (66.7%) < 0.001 0.003
Cardiovascular event 11 (2.2%) 1 (0.8%) 73 (6.5%) < 0.001 0.008
Cardiovascular death 0 (0.0%) 0 (0.0%) 13 (1.2%) 0.026 NS
Non-cardiovascular death 3 (0.6%) 3 (2.3%) 38 (3.4%) 0.004 NS
Abbreviations: ABI ankle brachial index, ADPKD autosomal dominant polycystic kidney disease, BMI body mass index, CKD chronic kidney disease, CKDoe CKD of
etiologies other than ADPKD, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate with the CKD-EPI formula, FGF-23 fibroblast growth factor 23,
IMT intima-media thickness, iPTH intact parathyroid hormone, NS not statistically significant, SBP systolic blood pressure
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D had lower IMT values than the other groups, however,
there was an intermediate rate of pathological ABI and
atheromatous plaque.
When the control of classic cardiovascular risk factors
was evaluated, patients with ADPKD had the worst
achievement of blood pressure targets (Table 1 and
Supplemental Figure 1). The rates of overweight and
obesity were like non-CKD patients. It should be note
that obesity was present in 34.9% of patients with
CKDoe, in 26.5% of patients with ADPKD and also in
26.3% of controls. Finally, it is also particularly note-
worthy the low percentage of statins treatment in
patients with CKD (Supplemental Table 2 (S2)). Only
slightly more than half of the patients received statins,
reaching LDL-c levels < 100 in only 50 and 39.8% of
them (ADPKD and CKDoe respectively). If we consider
an LDL-c target < 70mg/dL, the percentage of patients
who achieve this target is only 11 and 9.7% respectively.
In general, the number of CVE during the 4 year of
follow-up was very low (Tables 1 and 2). In a Cox
regression model adjusted for age, sex, obesity, and
tobacco use, ADPDK had the lowest incidence of CVE
in the three groups (HR 0.422, 95%CI 0.221–0.808,
p = 0.009) (Fig. 3).
Stage 3 ADPKD patients compared to non-CKD subjects
(control group)
A second analysis was performed, comparing only
ADPKD with stage 3 CKD to non-CKD subjects, in
order to better observe the specific effect of ADPKD in-
stead of the effect of severe loss of eGFR (Table 2 and
Supplemental Table 3). In this comparison, there were
no significant differences in age, gender, overweight, and
obesity; however, patients with ADPKD had higher rates
of hypertension and dyslipidemia. As expected, due to
their mild CKD, patients with ADPKD had lower levels
of hemoglobin and serum albumin, and higher levels of
potassium, parathormone, and uric acid. Interestingly,
no differences were found in phosphate or calcium
levels.
There was a lower lipid control rate among patients
with ADPKD, despite a higher number of patients in
statins treatment (Supplemental Table 4). Interestingly,
and despite their CKD, this was not associated to higher
Table 2 Comparison between controls and ADPKD patients with stage 3 CKD
Controls
n = 498 (89.7%)
ADPKD stage 3 CKD
n = 57 (10.3%)
p
Age (years) 53.69 ± 11.63 54.54 ± 11.73 NS
Male gender 262 (52.5%) 30 (52.6%) NS
Hypertension 163 (32.7%) 52 (91.2%) < 0.001
Dyslipidemia 157 (31.5%) 37 (64.9%) < 0.001
Creatinine (mg/dL) 0.84 ± 0.15 1.69 ± 0.35 < 0.001
eGFR (mL/min/1.73m2) 91.82 ± 16.94 41.13 ± 8.52 < 0.001
Macroalbuminuria 0 (0.0%) 5 (13.2%) < 0.001
Total cholesterol (mg/dL) 204.41 ± 35.63 187.42 ± 40.68 0.001
HDL-cholesterol (mg/dL) 54.36 ± 15.38 49.05 ± 12.37 0.020
LDL-cholesterol (mg/dL) 128.73 ± 32.74 111.12 ± 31.93 < 0.001
Triglycerides (mg/dL) 112.32 ± 66.08 132.82 ± 64.99 0.030
Hemoglobin (g/dL) 14.54 ± 1.41 13.56 ± 1.35 < 0.001
Albumin (g/dL) 4.36 ± 0.30 4.23 ± 0.32 0.008
Uric acid (mg/dL) 5.05 ± 1.45 6.80 ± 1.28 < 0.001
iPTH (pg/mL) 53.54 ± 15.34 96.79 ± 46.94 < 0.001
Potassium (mEq/L) 4.47 ± 0.40 4.61 ± 0.45 0.017
DBP (mmHg) 79.84 ± 9.66 83.53 ± 9.35 0.006
Overweight (BMI 25.1–30 Kg/m2) 236 (47.3%) 23 (46.9%) < 0.001
Target LDL-cholesterol 349 (80.4%) 23 (46.9%) < 0.001
Cardiovascular event 11 (2.2%) 0 (0.0%) NS
Cardiovascular death 0 (0.0%) 0 (0.0%) –
Non cardiovascular death 3 (0.6%) 1 (1.8%) NS
Abbreviations: ABI ankle brachial index, ADPKD autosomal dominant polycystic kidney disease, BMI body mass index, CKD chronic kidney disease, DBP diastolic
blood pressure, eGFR estimated glomerular filtration rate with the CKD-EPI formula, FGF-23 fibroblast growth factor 23, HDL high density lipoprotein, IMT intima-
media thickness, iPTH intact parathyroid hormone, LDL low density lipoprotein, NS not statistically significant, SBP systolic blood pressure
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percentages of asymptomatic CVD: no difference was
found on IMT, the presence of plaque or pathologic
rates of ABI. The low number of CVE during the follow-
up (11 in the control group and none in the ADPKD
group) did not allow for comparison.
Discussion
To the best of our knowledge, this is the first study to
assess the adequacy of the control of traditional cardio-
vascular risk factors in ADPKD, and their impact on
asymptomatic CVD. In this large national prospective
cohort, patients with ADPKD have an intermediate risk
factors control rate, with a variable impact on subclinical
atheromatosis but with a lower event rate compared to
patients with CKDoe. Patients with ADPKD in CKD
stage 3 have a similar blood pressure control, while they
have a larger prevalence of hypertension and worse lipid
control than patients without CKD, but a similar rate of
asymptomatic CVD risk factors. It is to be noted that
the classic cardiovascular risk factors are not optimally
controlled.
Patients with ADPKD tend to be younger and health-
ier than patients with CKD who are affected from other
etiologies. Although cardiovascular morbidity is lower
compared to others causes of end-stage kidney disease
(ESKD), patients with ADPKD continued to have higher
cardiovascular morbidity and mortality [12]. A direct
link between ADPKD and metabolic abnormalities lead-
ing to CVD has been proposed [13]. In addition, total
kidney volume has been shown to be a predictor of CVE
[14]. Hypertension occurs early in the course of the dis-
ease, among other causes due to local hyperactivation of
the RAAS (Fig. 1) [15].
When a CVE occurs, it is expected to be more severe
than in the general population. A study that analyzed
episodes of acute myocardial infarction showed that
patients with ADPKD had a higher rate of ST-segment
elevation, multi-vessel involvement, and secondary
sudden death [16]. However, most studies have focused
on the evaluation and progression of CKD [17, 18].
Strict control blood pressure (BP) has been shown not
to slow the progression of CKD, but to improve the
damage in target organs [12]. However, The HALT PKD
trial carried out in an early population with ADPKD
showed that intensive control of systolic BP to 95–110
mmHg was associated with a 14% slower rate of kidney
volume growth compared to standard control [19]. Of
interest, other sub analysis of this trial found that
Fig. 3 Adjusted Cox regression model of cardiovascular event free time: controls vs. ADPKD vs. CKD of other etiologies. Kaplan Meier analysis: log
rank test: p < 0.001. Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease. Cox regression model
adjusted to age, sex, obesity and tobacco use
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sodium restriction is beneficial in the management of
ADPKD [20].
In our study, patients with ADPKD CKD stage 3
showed a cardiovascular profile similar to controls, with
similar results in ABI and even a better subclinical ather-
omatosis profile measured by ITM in both groups of the
study with an identical mean age. This may be related to
early and regular monitoring in patients with ADPKD.
Being a hereditary condition, early diagnosis is frequent,
leading to an early control of cardiovascular risk and the
intensification of treatments for cardiovascular preven-
tion. While this is not usually the case in the general
population, as has been shown in the control group.
Data on cardiovascular risk and evaluation and pre-
vention of CVD in patients with ADPKD is scarce. IMT
represent an early marker of vascular dysfunction [21].
Several studies have shown higher IMT values in ADPK
D than in healthy controls, even before the development
of hypertension [22–26]. In our cohort, patients with
ADPKD had the lowest IMT, while patients with ADPK
D CKD stage 3 presented a similar IMT to controls.
Previous studies have shown very similar values of IMT,
although they were performed in patients with ADPKD
with normal renal function [23]. This difference can be
explained by the fact that, for the present study, the con-
trols were not completely healthy subjects, but patients
recruited from primary care with different comorbidities.
The presence of plaque in the carotid or femoral arter-
ies may be considered established CVD, a late-stage or
asymptomatic CVD [27]. In our study, patients with
ADPKD had an intermediate rate of plaque presence
between controls and subjects with CKDoe, while stage
3 CKD ADPKD was not associated with higher rates of
atheromatous plaques than controls. As far as we know,
no other study has reported similar findings. Asymptom-
atic peripheral vascular disease is relatively common in
CKD [28]. ABI is a proved marker of CVD, and both
low and high values have shown to predict CVE in pa-
tients with CKD [29]. Pathologic rates of ABI values
were lower in patients with ADPKD than in CKDoe, and
similar to controls without CKD. A previous study
showed a normal ABI value in patients with ADPKD
with an eGFR > 60mL/min [30].
In this cohort, BP and weight control were not lower
than controls or patients with CKDoe, as long as BP
control is understood as for general CKD patients, not
as for the intense control recommended for ADPKD
patients [17]. Despite more frequent use of statins, LDL
control was lower than controls and similar to other
patients with CKD. One possible explanation could be
the use of insufficient statin doses. In general terms, the
adequacy of the control of cardiovascular risk factors in
patients with ADPKD observed in our study may be
responsible for the low rates of asymptomatic CVD.
Lipid control also appears to affect the progression of
CKD in ADPKD; however, the actual pleiotropic effect
of statins remains unclear [17, 31]. Other studies have
shown worse lipid control and higher uric acid levels
and inflammatory markers, also not associated with
worse IMT or ABI [30]. These results could be influ-
enced not only by serum lipid levels, but also by deeper
lipid disturbances, such as lipid particle number, size
and density. These alterations have been related to CVD
in CKD of other etiologies [32], and recently preliminary
data have been published in this regard in patients with
ADPKD [33].
The small differences between patients with ADPKD
at stage 3 of CKD and controls support the hypothesis
that the main cause for CVD in the ADPKD population
is CKD rather than the disease itself. While recognizing
that the control population is not completely healthy, its
cardiovascular status is similar to that of patients with
CKD stage 3 ADPKD, suggesting that a good control of
the risk factors for CV in ADPKD should allow ESKD to
be achieved in a good cardiovascular health.
Therefore, there is scope to improve cardiovascular
risk control in ADPKD, although most indications have
a low level of evidence based on expert opinions [34, 35].
Recent CVD guidelines [36] have established the CKD
condition as high or very high risk with the BP target
below 140/90 with a tendency to a systolic BP of 130 in
CKD if tolerated [36]. In our study, only half of the
patients achieved the less strict BP target. Recently
the ESC/EAS Guidelines for the management of
dyslipidemias have also considered CKD patients as
high or very high risk with LDL cholesterol objectives
of 70 mg/dL and 55 mg/dL respectively [37], being
these levels far from the data shown in our study.
The high prevalence of overweight and obesity in
patients with CKD, including patients with ADPKD,
coupled with the lack of achievement of BP and lipid
targets means that much remains to be done. These
data show the need to increase awareness about intensify-
ing the control of classic cardiovascular risk factors in
patients with ADPKD. It does not make much sense to
use expensive disease modifying drugs without using
effective adjuvant therapies that prevent CVE.
A deeper view of CVD and atheromatous disease is
needed in the near future. In this study, patients with
ADPKD-derived CKD showed a similar or even lower
long-term cardiovascular risk than those with or without
CKD. Given the condition of hereditary disease, in most
cases patients with ADPKD have benefited from routine
vascular evaluation tests because they have begun their
follow-up from the early stages. This have demonstrated
a prognostic effect, as we have shown in our study.
However, we are still far from achieving the optimal ob-
jectives for the control of cardiovascular risk factors.
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Finally, a major effort must be made to look beyond
the prevention of the progression of CKD, towards a
more intense management of cardiovascular risk, which
should lead to a reduction in CVE, especially if it could
be implemented early in the course of the disease.
Our study has several limitations. The main one is the
existence of an intentional selection bias: since patients
with previous CVE were excluded from the study,
included patients had a starting lower cardiovascular
profile. Besides, non-CKD patients are not matched
healthy controls. However, the control group had a
mean age like those in the ADPKD group. Finally, there
were many dropouts through the follow-up, mainly due
to kidney transplantation. Another limitation is related
to relatively low patients with ADPKD included. The
study also has important strengths, being the main its
large sample, and its multicenter and prospective nature.
In conclusion, patients with ADPKD show intermedi-
ate control rates of cardiovascular comorbidities, when
compared to non-CKD subjects and other etiologies of
CKD. Better control of cardiovascular risk factors
appears to be associated with a lower burden of CVD,
which may lead in the long term to a better prognosis.
However, we are still far from achieving the optimal
goals for the control of cardiovascular risk factors in
patients with ADPKD. Further investigation is needed to
deepen our knowledge about the course of CVD in
ADPKD and to determine the usefulness of specific
therapeutic measures to improve cardiovascular progno-
sis in ADPKD.
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